Genmab develops fully human, high affinity antibodies to treat life-threatening and debilitating diseases. Some of our HuMax antibodies have been shown to be 100 to 1000 times better at finding and binding to their disease target than earlier generations of murine or laboratory-engineered antibodies which are not fully human. In addition, we believe that fully human antibody therapies may have other advantages over older generation products, such as a more favorable safety profile and improved treatment regimens.

A number of Genmab's antibodies are currently available for licensing. Click on each product for more information.

Zalutumumab - oncology
A fully human antibody targeting EGFr, a validated tumor target.

HuMax-HepC - infectious disease
An IND-ready antibody for the prevention of HCV reinfection in liver transplant recipients. 

HuMax-TAC - autoimmune disease, oncology, organ transplantation

Recent preclinical data demonstrate improved properties over existing therapies. A potential bio-better in Multiple Sclerosis. 

Genmab’s technologies are also available for either licensing or to strategic partners interested in participating in the development of therapies derived from these technologies.

Genmab’s DuoBody™ platform for bispecific antibody development
Genmab’s UniBody® technology

For more information on licensing opportunities at Genmab, please contact our Business Development department at licensing@genmab.com.